Damora Therapeutics, Inc.
DMRA
$20.96
$0.050.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -27.78M | -200.74M | -3.13M | -3.44M | -2.53M |
| Total Depreciation and Amortization | 68.00K | 7.00K | 10.00K | 9.00K | 8.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.13M | 184.16M | 175.00K | 174.00K | 209.00K |
| Change in Net Operating Assets | 3.98M | 17.14M | 332.00K | 1.02M | -123.00K |
| Cash from Operations | -20.60M | 566.00K | -2.62M | -2.24M | -2.44M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -17.37M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -17.37M | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 316.67M | 33.00K | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 266.81M | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -20.75M | -- | -- | -- | -- |
| Cash from Financing | 295.92M | 266.84M | -- | -- | -- |
| Foreign Exchange rate Adjustments | -48.00K | -18.00K | 11.00K | 509.00K | 203.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 275.28M | 250.02M | -2.61M | -1.73M | -2.24M |